What is the Generalized Anxiety Disorder Market Size in 7MM?
What is Generalized Anxiety Disorder?
Generalized anxiety disorder involves persistent and
excessive worry that interferes with daily activities. This ongoing worry and
tension may be accompanied by physical symptoms, such as restlessness, feeling
on edge or easily fatigued, difficulty concentrating, muscle tension, or
problems sleeping. Often the worries focus on everyday things such as job
responsibilities, family health, or minor matters such as chores, car repairs,
or appointments. GAD can go undiagnosed because of a focus on physical symptoms
and the stigma of mental illness. However, people with GAD can have meaningful
lives and can function socially as well, when the anxiety level is
mild-to-moderate or when they are taking some kind of treatment.
The Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-V) lists separation anxiety, selective mutism, specific
phobia, social anxiety disorder (also called social phobia), panic disorder,
agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety,
and an anxiety disorder caused by another medical condition. The criteria of
GAD in DSM-V include the characteristics such as feeling restless, keyed up, or
on edge, fatiguing easily, difficulty concentrating or the mind going blank,
irritability, increased muscle tension, difficulty falling asleep, staying
asleep, or restlessness. Excessive worry and anxiety occur most of the time for
at least 6 months, with at least three of the core symptoms in adults and one
sign in the case of children.
According to the Anxiety and Depression Association of
America (ADAA), in any given year, GAD affects 6.8 million adults or 3.1% of
the US population. Women are twice as likely to be affected. Although the exact
cause of GAD is unknown, there is evidence that biological factors, family
background, and life experiences, particularly stressful ones, play a role.
What are the Generalized Anxiety Disorder Emerging Drugs?
To meet the current demands of the patient pool and to
counter the unmet needs of the therapeutic market, drug developers are
gradually shifting their attention toward GAD as a possible indication for new
targeted therapies. Several companies are working robustly on many new
therapies, such as MM-120 (Mind Med) and PH49B (VistaGen’s Therapeutics). The
mid-stage pipeline is crowded, with several potential therapies with the
imminent attention of big pharmaceutical companies for this market space.
MM-120 (Mind Med) is a pharmacologically optimized form of
lysergic acid diethylamide (LSD; it has been investigated for its applications
in the treatment of anxiety associated with terminal cancer, alcoholism, opioid
use disorder, and depression, among other conditions). The drug is a
psychedelic drug being developed for GAD and other brain-based disorders and
can cause intensified thoughts, emotions, and sensory perception. At
sufficiently high dosages, MM-120 manifests primarily in visual, as well as
auditory, hallucinations. MM-120 is currently in Phase II b clinical trial for
GAD. MindMed is working with study investigators and clinical trial sites to
prepare for participant enrollment, which is expected to start in early 2022.
PH49B (VistaGen’s Therapeutics) is an innovative synthetic
investigational neurosteroid developed from proprietary compounds called
pherines. With its novel mechanism of action, PH94B is an odorless nasal spray
administered at microgram-level doses to achieve rapid-onset anti-anxiety, or
anxiolytic, effects. The pharmacological activity of PH94B is fundamentally
differentiated from that of all FDA-approved anti-anxiety drugs. Importantly,
PH94B does not require systemic uptake and distribution to produce its
rapid-onset anti-anxiety effects. In all clinical trials to date, PH94B’s
safety profile has been excellent, with placebo-like side effects and no serious
adverse events like those that are associated with the current FDA-approved
treatment options. The drug is currently in Phase II for the treatment of
generalized anxiety disorder.
Discover which therapies are expected to grab major
Generalized Anxiety Disorder market share @ Generalized
Anxiety Disorder Market Forecast
What is the Generalized
Anxiety Disorder Market Size in 7MM?
The total generalized anxiety disorder market
size was accounted for USD 1,500 million in the year 2021 and is estimated to
grow during the study period (2019-2032).
What is the Generalized
Anxiety Disorder Market Outlook?
The Generalized Anxiety Disorder market outlook of the
report builds a detailed comprehension of the historical, current, and
forecasted Generalized Anxiety Disorder market trends by analyzing the impact
of current therapies on the market, unmet needs, and demand for better
technology. This segment gives a thorough detail of the Generalized Anxiety
Disorder market trend of each marketed drug and late-stage pipeline therapy by
evaluating their impact based on the annual cost of therapy, inclusion and
exclusion criteria’s, mechanism of action, compliance rate, growing need for
the market, increasing patient pool, covered patient segment, expected launch
year, competition with other therapies, brand value, their impact on the market
and view of the key opinion leaders. The calculated market data are presented
with relevant tables and graphs to give a clear view of the market at first
sight.
Who are the leading companies in the Generalized Anxiety
Disorder Market Landscape?
The key players in the Generalized anxiety disorder market
who are in different phases of developing Generalized anxiety disorder
Therapies are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals,
Bionomics and others.
What are the Key strengths of the Generalized
Anxiety Disorder Market Report?
Key strengths of the generalized anxiety disorder Market
Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market
Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers,
along with the upcoming market trends in the generalized anxiety disorder
Market.
Which country is expected to account for the most
significant prevalent cases for Generalized Anxiety Disorder in the 7MM?
The United States is expected to account for the highest
prevalent Generalized Anxiety Disorder cases.
Discover more about drugs for Generalized Anxiety
Disorder in development @ Generalized
Anxiety Disorder Market Trends
1. Trending
Healthcare Market Research Reports
2. Technical
Due Diligence Firms
7. B-Cell Maturation Antigen Targeted Therapies Market
9. Oncolytic Virus Cancer Therapy Pipeline
10. Shingles Market
About Us
DelveInsight is a Business Consulting and Market research
company, providing expert business solutions for the healthcare domain and
offering quintessential advisory services in the areas of R&D, Strategy
Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and
Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
Comments
Post a Comment